These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36930502)

  • 1. Potential biomarkers for the prognosis and treatment of HCC immunotherapy.
    Li H; He Q; Zhou GM; Wang WJ; Shi PP; Wang ZH
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2027-2046. PubMed ID: 36930502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening Prognosis-Related lncRNAs Based on WGCNA to Establish a New Risk Score for Predicting Prognosis in Patients with Hepatocellular Carcinoma.
    Zhou X; Dou M; Liu Z; Jiao D; Li Z; Chen J; Li J; Yao Y; Li L; Li Y; Han X
    J Immunol Res; 2021; 2021():5518908. PubMed ID: 34426790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
    Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
    BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a disease-specific lncRNA-miRNA-mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma.
    Zhang Q; Sun L; Zhang Q; Zhang W; Tian W; Liu M; Wang Y
    Cancer Med; 2020 Dec; 9(24):9219-9235. PubMed ID: 33232580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
    Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
    BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of immune-infiltrating cell-related biomarkers in hepatocellular carcinoma based on gene co-expression network analysis.
    Hou Y; Zhang G
    Diagn Pathol; 2021 Jul; 16(1):57. PubMed ID: 34218795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma.
    Tang Y; Zhang H; Chen L; Zhang T; Xu N; Huang Z
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
    Li R; Jin C; Zhao W; Liang R; Xiong H
    BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma.
    Zhang L; Tao H; Li J; Zhang E; Liang H; Zhang B
    Aging (Albany NY); 2021 May; 13(12):15990-16008. PubMed ID: 34049287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.
    Chen R; Chen Y; Huang W; Zhao Y; Luo W; Lin J; Wang Z; Yang J
    Aging (Albany NY); 2021 Jul; 13(13):17607-17628. PubMed ID: 34237706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
    Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
    Front Immunol; 2021; 12():653836. PubMed ID: 33897701
    [No Abstract]   [Full Text] [Related]  

  • 17. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy.
    Wu H; Liu TT; Feng YM; Xie XY; Su XN; Qi JN; Zhu Q; Qin CY
    J Dig Dis; 2020 Nov; 21(11):650-663. PubMed ID: 32959529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.